Navigation Links
SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009
Date:11/17/2009

TSX symbol: SBS

CALGARY, Nov. 17 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. ("SemBioSys") (TSX:SBS) today announced that the Court of Queen's Bench of Alberta has issued an interim order authorizing SemBioSys to hold a special meeting of the securityholders of SemBioSys, at which securityholders will be asked to approve the proposed plan of arrangement (the "Arrangement") involving the corporate reorganization with Cathedral Energy Services Income Trust ("Cathedral"), which was announced on October 30, 2009.

SemBioSys will hold a special meeting of securityholders at 8:00 a.m. (MT) on Friday, December 18, 2009 at the corporate offices of McCarthy Tetrault LLP, Suite 3300, 421 - 7th Avenue SW, Calgary, Alberta. The Court has fixed November 16, 2009 as the record date for determining the securityholders entitled to receive notice of and to vote at the SemBioSys special meeting. At such meeting, SemBioSys securityholders will be asked to approve the Arrangement between SemBioSys and Cathedral.

The management information circular of SemBioSys, as well as the related proxy forms are expected to be mailed to the shareholders of SemBioSys on or about November 20, 2009.

For the Arrangement to be implemented (a) the Arrangement must be approved at the SemBioSys special meeting by a resolution passed by at least 66 2/3 percent of the votes cast by the securityholders of SemBioSys, and (b) at the Cathedral special meeting of unitholders to be held on the same date as the SemBioSys special meeting, the Arrangement must be approved by a resolution passed by at least 66 2/3 percent of the votes cast by the unitholders of Cathedral.

The Arrangement is also subject to the satisfaction or waiver of certain conditions set forth in the arrangement agreement dated October 29, 2009, as amended between SemBioSys, Cathedral, Cathedral Energy Services Ltd., 1491265 Alberta Ltd. and 1491277 Alberta Ltd. (which can be found at www.sedar.com) and to the final approval of the Court of Queen's Bench of Alberta. Assuming that all required securityholder and unitholder approvals are obtained, SemBioSys is expected to apply to the Court in December 2009 for a final order in respect of the Arrangement. The date and time of presentation for the hearing of the application for final order before the Court will be announced by a news release which will be issued and posted on SemBioSys' website. Assuming that the final order is obtained and all other conditions precedent to the Arrangement are satisfied or waived, the Arrangement is expected to close on or before December 21, 2009.

About SemBioSys

Calgary, Alberta-based SemBioSys is focused on leveraging its unique proprietary platform to manufacture high-value proteins and oils. SemBioSys' seed-based protein production system can provide for its partners product enablement, exceptionally low cost and unprecedented scalability. SemBioSys is applying the platform with high selectivity to products with tremendous clinical promise and value potential. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of court and other regulatory approvals and consents, the obtaining of securityholder approvals, any adjustment with respect to the amount of the non-dilutive financing, including the market price of the securities to be received by New SemBioSys, the satisfaction of closing conditions, and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise,

SOURCE SemBioSys Genetics Inc.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys announces third quarter 2009 financial and operational results
2. SemBioSys provides an update on Botaneco
3. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
4. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
5. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
6. SemBioSys provides update on insulin program
7. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
8. SemBioSys announces senior management changes
9. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
10. SemBioSys begins phase I/II trial of insulin produced in plant seeds
11. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Palo Alto, CA (PRWEB) , ... September 20, ... ... and public interest organization focused on molecular manufacturing and other transformative technologies, announced ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/19/2017)... ... 19, 2017 , ... Participants of this educational webinar will ... Along with the advantages and disadvantages of ductless, filtered fume hoods, they will ... laboratory. , Attendees will learn from an industry expert about the different types ...
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® pocket ... testers even stand upright with a new cap design that is versatile, functional and ... field who need to test water quality. , The Oakton pocket testers have many ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... is pleased to announce the recipients of its 2017 Science Student Award. The ... leadership qualities, and involvement with community service defray the costs of obtaining their ...
Breaking Biology Technology:
(Date:8/15/2017)... HAMPTON, Va. , Aug. 15 2017   ivWatch LLC ... effectiveness of intravenous (IV) therapy, today announced receipt of its ISO ... (QMS) developed by the International Organization for Standardization (ISO┬«). ... ivWatch Model 400 Continuous Monitoring device for ... "This ...
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):